[Click eStock] "Lunit, Expected to Expand Entry into Global Medical AI Market"

Hana Securities stated on the 18th that "Lunit is expected to achieve 38% revenue growth as it expands its entry into the global medical artificial intelligence (AI) market."

On the same day, Han Yu-geon, a researcher at Hana Securities, said, "Lunit's expected performance this year is projected to record sales of 74.5 billion KRW, a 37.5% increase from the previous year, and an operating loss reduced to 56 billion KRW."

He added, "The acquisition of Volpara will strengthen competitiveness in the U.S. market, and the possession of differentiated data and AI algorithms compared to other companies, along with the expansion of sales of the Lunit Insight product, will drive growth."

Lunit is a global medical AI company that has developed and commercialized diagnostic assistance solutions that complement visual limitations through deep learning technology. Its main products include Lunit Insight, an imaging diagnostic assistance solution related to cancer diagnosis, and Lunit Scope, an imaging biomarker solution related to cancer treatment. Researcher Han said, "Lunit has established overseas sales networks by forming partnerships with global medical device manufacturers such as GE Healthcare, Philips, Hologic, and Fujifilm."

In particular, through Volpara Healthcare, a New Zealand-based company acquired last May, business development utilizing the U.S. distribution network is expected to become more active. Researcher Han analyzed, "Through Volpara, it is possible to secure 20 million new data annually, and through data internalization efforts, the advancement of the Lunit Insight product and contribution to performance are expected to expand."

Lunit was also the only company selected for a government-led national cancer screening project in Australia that provides free breast cancer screening every two years for women over 40. This is regarded as a successful case of entering the global B2G (business-to-government) market. After verification, the product is currently being applied in actual medical settings. Researcher Han said, "A revenue of 3 Australian dollars per case is expected, and with long-term reference acquisition, business expansion to regions such as Singapore and the Middle East is anticipated."

Additionally, Researcher Han stated, "Lunit's AI biomarker platform, Lunit Scope, signed a strategic contract last November with global pharmaceutical company AstraZeneca to develop digital pathology solutions," and added, "It is understood that they are preparing to expand with various products such as AI for predicting immune checkpoint inhibitor responses and AI for stained slide analysis." He also mentioned, "Discussions are ongoing with many big pharma companies besides global pathology firms, and visible results are expected within this year."

This content was produced with the assistance of AI translation services.